An Observational Post-Authorization Safety Study (PASS) of MOVENTIG® (Naloxegol) Drug Utilization in Selected European Populations

Trial Profile

An Observational Post-Authorization Safety Study (PASS) of MOVENTIG® (Naloxegol) Drug Utilization in Selected European Populations

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Naloxegol (Primary)
  • Indications Constipation
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 03 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 11 Jul 2016 Planned initiation date changed from 1 Jun 2016 to 1 Jul 2016.
    • 08 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top